Palbociclib, trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer: randomised phase II, SOLTI-1303 PATRICIA trial

医学 曲妥珠单抗 内科学 肿瘤科 养生 中性粒细胞减少症 临床终点 不利影响 危险系数 队列 转移性乳腺癌 乳腺癌 临床研究阶段 内分泌系统 毒性 化疗 临床试验 无进展生存期 中止 外科 随机对照试验 癌症
作者
Eva Ciruelos,Tomás Pascual,Guillermo Villacampa,Sonia Pernas,Rodrigo Sanchez-Bayona,Jose Ponce,Blanca Cantos,Santiago Escrivá-de-Romani,Antonia Perelló,Esther Sanfeliu,Patricia Galván,Alvaro Montaño,Eduardo Martínez,Ana López,Mireia Melé,Juan de la Haba,Javier Cortés,Antonio Mulero-Sánchez,Juan M Ferrero-Cafiero,Mafalda Oliveira
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
标识
DOI:10.1158/1078-0432.ccr-25-2882
摘要

Abstract Purpose: Based on the results from SOLTI-PATRICIA trial (NCT02448420) cohorts A/B, a direct comparison with standard-of-care treatments is needed to evaluate the efficacy and safety of palbociclib, trastuzumab and endocrine therapy (ET) in PAM50-luminal A/B pretreated patients. Patients and Methods: SOLTI-PATRICIA cohort C is a randomised, multicentre, prospective, open-label, phase II study. Pretreated patients with HER2-positive, HR-positive, and PAM50-Luminal A/B ABC were randomised 1:1 to receive either i) the triplet regimen or ii) trastuzumab-based treatment of physician’s choice (TPC). Patients allocated in the TPC arm were eligible for re-randomization upon disease progression, if the inclusion criteria were still met. The primary endpoint was investigator-assessed progression-free survival (PFS) per RECIST 1.1. Results: 264 participants were pre-screened between August 2019-2023, and 73 patients were randomised (including seven re-randomisations). In the TPC arm: 48.5% were treated with trastuzumab plus chemotherapy, 39.4% with T-DM1 and 12.1 % with trastuzumab plus ET. The triplet was associated with a significantly better PFS compared to TPC (stratified hazard ratio=0.52 [95% CI 0.29–0.95]; two-sided p=0.03). PFS rates after 24 months were 24.0% with the triplet and 4.3% in the TPC arm. The overall response rate was 18.9% (95% CI 8.6–35.7) and 7.1% (95% CI 1.2–25.0), respectively. In the triplet arm, grade ≥3 adverse events occurred in 61.5% of patients, with neutropenia being the most frequent (53.9%). No permanent discontinuations due to toxicity were observed. Conclusions: Combining palbociclib, trastuzumab, and ET was safe and improved significantly PFS, compared to TPC in previously treated HER2-positive, PAM50 luminal A/B ABC patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
miracloon完成签到,获得积分10
1秒前
wangjue发布了新的文献求助10
2秒前
Lucas的应助被Vincent采纳,获得10
2秒前
4秒前
在水一方的应助被科研通管家采纳,获得10
7秒前
科研通AI2S的应助被科研通管家采纳,获得10
7秒前
20230054完成签到,获得积分10
9秒前
赘婿的应助被Vincent采纳,获得10
10秒前
11秒前
lq完成签到 ,获得积分10
12秒前
wangjue完成签到,获得积分10
15秒前
李健的小迷弟的应助被Vincent采纳,获得10
16秒前
17秒前
22秒前
wu完成签到 ,获得积分10
27秒前
JamesPei的应助被Vincent采纳,获得10
27秒前
苹果元灵完成签到,获得积分10
28秒前
28秒前
666666神花露水完成签到 ,获得积分10
31秒前
NexusExplorer的应助被Vincent采纳,获得10
34秒前
34秒前
yu完成签到 ,获得积分10
35秒前
41秒前
爆米花的应助被Vincent采纳,获得10
43秒前
47秒前
HAPPY完成签到,获得积分10
48秒前
桐桐的应助被Vincent采纳,获得10
49秒前
keleboys完成签到 ,获得积分10
51秒前
HMZ完成签到 ,获得积分10
53秒前
54秒前
HU完成签到 ,获得积分10
56秒前
57秒前
1分钟前
小尾巴完成签到 ,获得积分10
1分钟前
章鱼行者完成签到,获得积分10
1分钟前
鲁文杰发布了新的文献求助10
1分钟前
Maestro_S的应助被Vincent采纳,获得10
1分钟前
1分钟前
万能图书馆的应助被Vincent采纳,获得10
1分钟前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190366
求助须知:如何正确求助?哪些是违规求助? 9577437
关于积分的说明 21852521
捐赠科研通 7788988
什么是DOI,文献DOI怎么找? 3436315
关于科研通互助平台的介绍 2560144
邀请新用户注册赠送积分活动 2482995